Calcimedica, INC Form 4 insider transactions

Sudarshan Hebbar, Chief Medical Officer of CalciMedica, Inc., received 180,000 shares of common stock on September 24, 2026.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., received 180,000 shares of common stock on September 24, 2026.

Stephen Bardin, Chief Financial Officer of CalciMedica, Inc., received 190,000 shares of common stock on September 24, 2026.

A. Rachel Leheny, CHIEF EXECUTIVE OFFICER and a Director of CalciMedica, Inc., received 360,000 shares of common stock on September 24, 2026.

Alafi Capital Co Llc reported changes in beneficial ownership of CalciMedica, Inc. common stock on August 19, 2026.

Allan Shaw, a Director of CalciMedica, Inc., received 10,000 shares of common stock on August 19, 2026.

Alan Glicklich, a Director of CalciMedica, Inc., received 10,000 shares of common stock on August 19, 2026.

Frederic Guerard, a Director of CalciMedica, Inc., received 10,000 shares of common stock on August 19, 2026.

Evgeny Zaytsev, a Director of CalciMedica, Inc., reported multiple transactions in common stock on August 19, 2026.

Robert N Wilson, a Director of CalciMedica, Inc., reported multiple transactions in common stock on August 19, 2026.

Sudarshan Hebbar, Chief Medical Officer of CalciMedica, Inc., reported multiple transactions in common stock on August 19, 2026.

Eric W Roberts, CHIEF BUSINESS OFFICER and a Director of CalciMedica, Inc., reported multiple transactions in common stock on August 19, 2026.

A. Rachel Leheny, CHIEF EXECUTIVE OFFICER and a Director of CalciMedica, Inc., reported multiple transactions in common stock on August 19, 2026.

CalciMedica, Inc. reports that Director Evgeny Zaytsev acquired stock options for 20,000 shares.

Fred A. Middleton, a Director and 10% Owner of CalciMedica, Inc., acquired 248,972 shares of common stock on June 25, 2026, through a Securities Purchase Agreement.

CalciMedica Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of common stock.

CalciMedica Director Robert N. Wilson acquired over 1.1 million shares of common stock in a private placement.

Eric W. Roberts, a Director and Chief Business Officer of CalciMedica, Inc., acquired 186,729 shares of common stock on June 25, 2026, through a Securities Purchase Agreement.

CalciMedica CEO Rachel Leheny acquired 186,729 shares of common stock in a private placement transaction on June 25, 2026.

CalciMedica, Inc. reports that Chief Financial Officer Stephen Bardin acquired employee stock options on April 5, 2026.

CalciMedica, Inc. (CALC) insider Sudarshan Hebbar reports on stock option transactions, detailing vesting schedules and potential future equity.

Eric W. Roberts, a Director and Chief Business Officer of CalciMedica, Inc., acquired employee stock options.

Michael J. Dunn, President and COO of CalciMedica, Inc., reported a transaction involving employee stock options.

CalciMedica, Inc. reports on stock option transactions by Chief Scientific Officer Kenneth A. Stauderman.

CalciMedica CEO Rachel Leheny reports the grant of employee stock options, with vesting contingent on an S-8 filing.

CalciMedica Director Alan Glicklich was granted 937 stock options with an exercise price of $3.26, vesting monthly starting October 1, 2025, under a 10b5-1 plan.

CalciMedica's Chief Business Officer, Eric W. Roberts, has filed a Form 4 indicating a planned purchase of 2,500 shares of common stock on September 18, 2025.

CalciMedica's Chief Business Officer, Eric W. Roberts, acquired 3,400 shares of common stock, signaling confidence in the company.

CalciMedica insider Eric W. Roberts discloses a planned acquisition of 5,000 shares of common stock for $3.12 per share on September 12, 2025.

CalciMedica's Chief Business Officer, Eric W. Roberts, acquired 2,343 shares of common stock through a Roth IRA at a weighted average price of $3.1488.